Technology | October 17, 2007

Guerbet’s Oxilan Offers Low Side Effects, Favorable Results


Guerbet’s X-ray contrast agent, Oxilan (ioxilan), is a nonionic low-viscous and low-osmolar monomer.
Significant characteristics of contrast media such as ionicity, chemical structure, osmolality and viscosity have important influences on their efficacy and safety. This emphasis has been implemented in the development of Oxilan, whose chemical characteristics have resulted in high quality imaging with minimal side effects, according to its manufacturer.

Related Content

Bracco and Blue Earth Diagnostics has announced the appointment of Marco Campione as new CEO, effective immediately. Campione succeeds David Gauden, D. Phil., who now assumes the role of CEO of Bracco subsidiary Blue Earth Therapeutics.
News | Radiology Business
Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
Swedish biotech company Ascelia Pharma has announced its liver imaging drug candidate, Orviglance, significantly improved visualization of focal liver lesions, having successfully met the primary endpoint in the pivotal Phase 3 study, SPARKLE. CEO Magnus Corftizen shown here, offered an update on the first-in-class contrast agent for use in liver MRI in patients with severely impaired kidney function which has been granted FDA Orphan Drug Designation.
News | Contrast Media
Ascelia Pharma Meets Primary Endpoint in Phase 3 Study of Orviglance Liver Imaging Contrast Agent Drug Candidate

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
LUMISIGHT and Lumicell Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from second surgeries
News | FDA
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
Ga-68 has a very short half-life, which presents logistical challenges in distribution
News | Radiopharmaceuticals and Tracers
RLS Radiopharmacies Partners with Eckert and Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
During the blood pool phase, it significantly shortens the T1 and T2 relaxation times of the blood, thus achieving bright blood effects in T1-weighted imaging and dark blood effects in T2/T2*-weighted imaging. In the delay phase, by the local aggregation of ferumoxytol disrupting the uniformity of the local magnetic field, the decrease of the transverse magnetization vector Mxy is expedited, resulting in a negative contrast effect.
News | Molecular Imaging
Exploring Ferumoxytol: A Frontier in MRI Contrast Agents

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
Lumicell announced the Medical Imaging Drugs Advisory Committee (MIDAC) of the U.S Food and Drug Administration (FDA) voted in support of the benefit-risk profile of LUMISIGHT
News | Breast Imaging
Lumicell Announces FDA Advisory Committee’s Positive Recommendation on the Benefit-Risk Profile of LUMISIGHT in the Detection of Cancerous Tissue During Breast Conserving Surgery

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Mid-Winter Conference drew global experts exchanging the latest innovations in diagnostic and molecular imaging, cancer therapies, clinical trials and theranostics, as well and the role of artificial intelligence (AI) in nuclear medicine during its Feb. 1-3, 2024 meeting in Orlando, FL.
News | SNMMI
Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter Conference Focuses on Theranostics, AI, Diagnostic Imaging Innovations and Clinical Trials

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
With its latest evolution, Guerbet reports that it offers advanced performance features to its Optistar Elite.
Feature | Contrast Media Injectors | By Christine Book
Market Analysis: Vendor Focus on Optimizing Patient Safety and Radiology Workflow Drives Growth

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway (gadopiclenol) in the European Union
News | Contrast Media
The European Commission Grants Marketing Authorization to Bracco Imaging for Vueway (gadopiclenol) Contrast Agent in the European Union

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
ELUCIRE (gadopiclenol) Injection Safety Data Poster Presentation
News | Interventional Radiology
Guerbet to Spotlight Diagnostic and Interventional Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time November 03, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now